A multiple ascending dose (MAD) safety, tolerability & efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in subjects with thyroid eye disease (TED)

This research project is a multiple ascending dose (MAD) clinical study evaluating the safety, tolerability and preliminary efficacy of VRDN-001, a humanized monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R), in subjects with thyroid eye disease (TED). The study is designed to systematically assess repeated dosing of VRDN-001 across escalating dose cohorts to determine the compound's safety profile, characterize adverse events and dose-limiting toxicities, and collect pharmacokinetic and pharmacodynamic data that inform dose selection for subsequent trials. As a targeted biologic agent, VRDN-001 aims to modulate pathogenic signaling mediated by IGF-1R that is implicated in the fibroproliferative and inflammatory processes underlying TED.

The MAD framework enables investigators to observe cumulative and steady-state effects of the antibody, to evaluate immune-related responses over time, and to observe any emerging signals of clinical benefit on ocular signs and symptoms of TED. Subjects enrolled in the trial will receive repeated administrations of VRDN-001 at prespecified ascending dose levels under careful monitoring. Safety assessments include monitoring for infusion reactions, immune-mediated adverse events, laboratory abnormalities, and any organ-specific toxicities that could arise from IGF-1R blockade. Tolerability assessments encompass patient-reported symptoms, tolerability during and after dosing, and the frequency and severity of adverse events across cohorts.

Efficacy endpoints are exploratory and intended to capture preliminary evidence of clinical activity in TED; these may include standardized ophthalmologic measures such as proptosis (exophthalmos), diplopia, clinical activity score (CAS), eyelid retraction, and patient-reported outcomes related to vision and quality of life. Pharmacokinetic sampling will quantify serum levels of VRDN-001 over time to define exposure, half-life, accumulation, and clearance, while pharmacodynamic assessments will evaluate biological effects on IGF-1R signaling pathways and downstream biomarkers relevant to TED pathophysiology. The ascending dose design permits careful dose escalation contingent on predefined safety criteria and independent data monitoring review, ensuring participant safety while enabling identification of dose-response relationships. Data generated from this MAD study will be pivotal in informing the optimal dosing regimen for subsequent phase 2 and phase 3 trials, refining inclusion criteria, and guiding biomarker strategies to select patients most likely to benefit from IGF-1R inhibition.

The study contributes to the therapeutic development pathway for targeted biologics in TED by providing essential early clinical characterization of VRDN-001's risk-benefit profile. Through systematic safety monitoring, integrated pharmacology assessments, and exploratory clinical outcome measures, the trial seeks to determine whether VRDN-001 has the potential to alter the disease course and improve ocular outcomes for patients suffering from thyroid eye disease.